CYP27A1 and lung carcinoma: A meticulous molecular docking analysis revealed that CTX‐1 exhibits a noteworthy binding affinity of −7.9 kcal/mol, challenging Erlotinib, a conventional lung cancer medication, which displayed a binding affinity of −7.3 kcal/mol.